WO2005041919A2 - Medikamentöse gezielte lokale lipolyse - Google Patents

Medikamentöse gezielte lokale lipolyse Download PDF

Info

Publication number
WO2005041919A2
WO2005041919A2 PCT/EP2004/011320 EP2004011320W WO2005041919A2 WO 2005041919 A2 WO2005041919 A2 WO 2005041919A2 EP 2004011320 W EP2004011320 W EP 2004011320W WO 2005041919 A2 WO2005041919 A2 WO 2005041919A2
Authority
WO
WIPO (PCT)
Prior art keywords
phospholipid
acid
use according
bile acid
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/011320
Other languages
German (de)
English (en)
French (fr)
Other versions
WO2005041919A3 (de
Inventor
Peter Boderke
Rainer Pooth
Juergen Sandow
Matthias Gossel
Karl-Heinz Nietsch
Gerhard Sattler
Gerhard Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005041919(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0415756-7A priority Critical patent/BRPI0415756A/pt
Priority to DE502004008793T priority patent/DE502004008793D1/de
Priority to HK07101847.6A priority patent/HK1096857B/xx
Priority to AU2004285264A priority patent/AU2004285264A1/en
Priority to MXPA06004081A priority patent/MXPA06004081A/es
Application filed by Sanofi Aventis Deutschland GmbH, Aventis Pharma Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to JP2006535989A priority patent/JP2007509085A/ja
Priority to EP04765912A priority patent/EP1684722B1/de
Priority to CA002543187A priority patent/CA2543187A1/en
Publication of WO2005041919A2 publication Critical patent/WO2005041919A2/de
Publication of WO2005041919A3 publication Critical patent/WO2005041919A3/de
Priority to IL174525A priority patent/IL174525A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to aqueous phospholipid systems containing at least one phospholipid, at least one bile acid and water, which are suitable for the production of medicaments for the treatment of adipose tissue diseases and lead to the regression of the pathologically proliferating adipose tissue.
  • Aqueous phospholipidic phospholipid systems are known for various applications. These systems are used, for example, in the cosmetics sector or for the manufacture of pharmaceutical products. These systems are characterized by the fact that they have spherical vesicles, also known as liposomes. The liposomes mentioned are limited to the outside by a lipid double membrane and contain an aqueous phase in their interior. Aqueous phospholipid systems containing at least one
  • Phospholipid, at least one bile acid and water are described, for example, in European patent application EP 0 615 746.
  • the product Lipostabil® N i.V. is commercially available. (Red List, March 2003), which is an aqueous phospholipid system that contains phospholipids, bile acid, DL-alpha-tocopherol, ethanol and water and is approved for the prophylaxis and treatment of fat embolism.
  • the liposome system used according to the invention leads to the regression of pathologically proliferated adipose tissue. It lipolysis of the adipose tissue occurs and the affected pathologically proliferating adipose area is reduced. As explained below, these diseases are not only aesthetically disfiguring proliferation of the adipose tissue, but painful conditions and impairments of body functions.
  • the invention therefore relates to the use of aqueous phospholipid systems containing a) at least one phospholipid, b) at least one bile acid and c) water for the production of a medicament for the treatment of fatty tissue diseases.
  • Another object of the invention is the use of the aqueous liposome system mentioned for the manufacture of a medicament for the regression of fatty tissue tumors.
  • phospholipid includes compounds such as 3-sn-phosphatidylcholine, soybean (Phospholipon 90), 3-sn-phosphatidylcholine, reduced soybean (Phospholipon 90H), 3- (3sn) -phosphohatidyi) glycerol soybean (Phospholipon G), dimyristoylphosphatidylglycol , Lysophosphatidylcholine or Dipalmitoylphosphatidylglycerol, as well as their physiologically acceptable salts understood.
  • Bile acid is understood to mean compounds such as deoxycholic acid, cholic acid, lithocholic acid, chenodesocycholic acid, hyodesoxycholic acid, trihydroxycoprostanoic acid, ursodeoxycholic acid, taurocholic acid or glycocholic acid, and their physiologically tolerable salts.
  • Dercum disease is a special form of hypertrophic proliferation of adipose tissue, which is located between the dermal fat fascia (Kampa fat fascia) and the underside of the dermis. Hormonal influences increase the water-binding capacity of these fat cells, which in turn cause pressure lymphatic congestion in the area of the initial herb-like lymphatic vessels and additional compression and irritation effects are exerted on the peripheral sensitive nerves, making these patients extremely painful to touch. Over the course of several years to decades, irregular fat nodules are formed, which are localized under the dermis, which becomes thinner as the aging process progresses, some of which are painful and strongly dysaesthetic.
  • Madelung's fat neck is a fat tissue-proliferating fatty tissue inflammation in which, in addition to dystrophic fat tissue tumor formation, scar-like connective tissue compaction in the subcutaneous area also occurs.
  • Surgical procedures can often only be partially successful, since essential anatomical structures are included in this process and the disease manifests itself essentially in the head, neck and shoulder area.
  • Lipedema is a painful swelling of the adipose tissue, which occurs particularly on the lower legs of women and has a progressive course or character with increasing age.
  • Piezogenic nodules are pressure-related hand edge nodules and heel nodules, which appear as multiple adipose tissue hernias, predominantly in the medial area of the heel in obese patients. It is usually defects in the septation of the subcutaneous adipose tissue that are cosmetically or functionally disruptive for patients.
  • Xanthelasma is a light yellow, slightly raised, plate-shaped deposit of cholesterol in the area of the eyelids. They are soft and easy to move and mostly appear symmetrically on both eyes. It arises due to local fat metabolism disorders. Women are particularly often affected after the menopause. Diabetes mellitus and high blood lipid levels are also at increased risk of developing it. Xanthelasms can be psychologically stressful because of their appearance.
  • lipodystrophy syndrome which can occur in HIV patients after treatment with protease inhibitors, dystrophia adiposogenitalis, which is an endocrine disorder in adolescent girls, sphingolipidoses, which are mostly hereditary in character, such as angiokeratoma corpis (Fabry syndrome) or gangliosidoses cutaneous manifestation.
  • regression means lipolysis of the adipose tissue and regression of the proliferated fat area.
  • adipose tissue diseases show pathologically clear tissue states or identities that can be represented by histological scarring and inflammation parameters, but also by Connective tissue encapsulation and by changes in the histological adipose tissue morphology itself.
  • the invention also relates to the use of aqueous phospholipid systems containing a) at least one phospholipid, b) at least one bile acid and c) water for the production of a medicament for the treatment of cellulite.
  • Cellulite is a special form of hypertrophic proliferation of adipose tissue, which is located between the dermal fat fascia (Kampa's fat fascia) and the underside of the dermis. Hormonal influences increase the water-binding capacity of these fat cells, which in turn is caused by pressure phenomena in the lymphatic congestion in the area of the initial fern-like
  • the invention also relates to the use of at least one phospholipid or at least one bile acid for the manufacture of a medicament for the treatment of fatty tissue diseases or cellulite. If only phospholipid or bile acid is used alone, the same conditions and definitions apply as for the above-mentioned mixtures of phospholipid and bile acid.
  • the invention also relates to the use of phospholipid, in which the phospholipid is present as a physiologically acceptable salt, for example as the sodium, potassium and / or ammonium salt.
  • the phospholipid can be isolated from oilseeds, rapeseed, soybeans or sunflowers and, after appropriate cleaning, can be used in the liposome system. Lecithin, for example from chicken eggs, is also suitable. Phospholipids from soybeans are preferred.
  • the invention also relates to the use of phospholipid, wherein the phospholipid is the phosphatidylcholine of the soybean and is isolated therefrom. Especially when the phospholipid consists of at least 90% by weight (% by weight) of soybean phosphatidylcholine, in particular 95% by weight.
  • the invention also relates to the use of a bile acid in which the bile acid is present as a physiologically acceptable salt.
  • a physiologically acceptable salt This is, for example, a sodium, potassium and / or ammonium salt of deoxycholic acid, cholic acid, lithocholic acid, chenodesocycholic acid, hyodesoxycholic acid, trihydroxycoprostanoic acid, ursodeoxycholic acid, taurocholic acid or glycolocholic acid.
  • the mass ratio of phospholipid to bile acid is in% by weight of
  • the phospholipid concentration in the liposome system is from 0.5% by weight to
  • the liposomes have a diameter of 30 nm to 180 nm, preferably from 30 nm to 130 nm, in particular from 50 nm to 90 nm. These liposomes can be sterile filtered without any problems, filters with a pore diameter of 0.2 ⁇ m then being used.
  • the pH of the liposome system is around the neutral point, preferably from 5.0 to 8.0, in particular from 6.2 to 7.4.
  • the liposome system is produced, for example, by dissolving or dispersing at least one phospholipid and at least one bile acid in the above-mentioned ratio to one another in an organic solvent. This solution or dispersion is then concentrated and then water is added, the liposome system being formed. After the water has been added, the production of the liposome system can be promoted by extrusion, high-pressure gap homogenization and / or ultrasound treatment. The treatment is carried out below 40 ° C, preferably from 20 ° C to 30 ° C. Suitable organic solvents are ethanol, propanol, isopropyl alcohol or benzyl alcohol, either alone or in a mixture.
  • the residual volumes of alcohols after concentration should be from 0% by volume (% by volume) to 20% by volume, preferably from 0% by volume to 10% by volume.
  • Methods for producing the liposome system are also described in European patent applications EP 0 470 437 or EP 0 615 746.
  • the liposome system used according to the invention is administered by subcutaneous, intra-articular, intraperitoneal, intramuscular or intravenous injection. Subcutaneous injection is preferred.
  • the liposome system used according to the invention should be uniformly introduced by means of a tumescence process which uses the hydrostatic pressure in order to ensure an even distribution.
  • Suitable forms of preparation are, for example, suspensions, emulsions or injectable solutions as well as preparations with a protracted release of active ingredient, the use of which is carried out using conventional auxiliaries.
  • the pharmaceutical preparations are preferably produced and administered in dosage units, each unit containing a certain dose of the liposome system as an active ingredient.
  • this dose can be from about 10 mg to about 2000 mg, preferably from about 50 mg to about 2000 mg, preferably from about 250 mg to 500 mg, based on the phospholipid.
  • daily doses of 5 mg to 500 mg, preferably 250 mg to 500 mg, per injection, based on the phospholipid, are necessary depending on the size of the treated adipose tissue when applying injection solutions.
  • the injection solutions can also be diluted before application, preferably with saline. Under certain circumstances, however, higher or lower daily doses may also be appropriate.
  • the dose is also dependent on the size of the lipomas, in the case of small lipomas, amounts of 1 mg to 50 mg, preferably 2 mg to 20 mg, per injection, based on the phospholipid, are completely sufficient.
  • the daily dose can be administered either as a single dose in the form of a single dose unit or else several smaller dose units or as a multiple dose divided at certain intervals.
  • Liposome diameter brought from 30 nm to 100 nm. The resulting liposome system was then sterilized
  • the patient had an approximately walnut-sized lipoma on the upper arm on the right.
  • the patient had no fat metabolism disorders and the serum lipids were within the normal range.
  • Example 3 Regression of pronounced cellulite The two patients had no lipid metabolism disorders and the serum lipids were within the normal range.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2004/011320 2003-10-24 2004-10-09 Medikamentöse gezielte lokale lipolyse Ceased WO2005041919A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002543187A CA2543187A1 (en) 2003-10-24 2004-10-09 Medicamentously targeted local lipolysis
EP04765912A EP1684722B1 (de) 2003-10-24 2004-10-09 Medikamentöse gezielte lokale lipolyse
HK07101847.6A HK1096857B (en) 2003-10-24 2004-10-09 Medicamentously targeted local lipolysis
AU2004285264A AU2004285264A1 (en) 2003-10-24 2004-10-09 Medicamentously targeted local lipolysis
MXPA06004081A MXPA06004081A (es) 2003-10-24 2004-10-09 Lipolisis local medicamentosa dirigida.
BRPI0415756-7A BRPI0415756A (pt) 2003-10-24 2004-10-09 lipólise medicamentosa local, dirigida
JP2006535989A JP2007509085A (ja) 2003-10-24 2004-10-09 薬物標的化された局所的脂肪分解
DE502004008793T DE502004008793D1 (cg-RX-API-DMAC7.html) 2003-10-24 2004-10-09
IL174525A IL174525A0 (en) 2003-10-24 2006-03-23 Medicamentously targeted local lipolysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10349979.2 2003-10-24
DE10349979A DE10349979B4 (de) 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse

Publications (2)

Publication Number Publication Date
WO2005041919A2 true WO2005041919A2 (de) 2005-05-12
WO2005041919A3 WO2005041919A3 (de) 2005-06-23

Family

ID=34529797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011320 Ceased WO2005041919A2 (de) 2003-10-24 2004-10-09 Medikamentöse gezielte lokale lipolyse

Country Status (13)

Country Link
EP (1) EP1684722B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509085A (cg-RX-API-DMAC7.html)
KR (1) KR20060117914A (cg-RX-API-DMAC7.html)
CN (1) CN100482211C (cg-RX-API-DMAC7.html)
AT (1) ATE418965T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004285264A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415756A (cg-RX-API-DMAC7.html)
CA (1) CA2543187A1 (cg-RX-API-DMAC7.html)
DE (2) DE10349979B4 (cg-RX-API-DMAC7.html)
ES (1) ES2319997T3 (cg-RX-API-DMAC7.html)
IL (1) IL174525A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004081A (cg-RX-API-DMAC7.html)
WO (1) WO2005041919A2 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699490A2 (de) * 2003-12-22 2006-09-13 Sanofi-Aventis Deutschland GmbH Medikament se lipolyse von fettansammlungen
RU2549966C2 (ru) * 2010-04-29 2015-05-10 Лихтблик Гмбх Применение фосфолипид-содержащей композиции для удаления подкожных скоплений жира посредством подкожного липолиза
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US11298314B2 (en) 2017-04-21 2022-04-12 Ami Pharm Co., Ltd. Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372499T3 (es) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
CN102481305B (zh) 2009-08-25 2015-08-19 美德阿利克斯株式会社 磷脂酰胆碱的经皮组合物及其制备方法
KR101353443B1 (ko) * 2012-02-07 2014-01-29 주식회사 아미팜 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법
BR112014029188B1 (pt) * 2012-05-31 2020-02-11 Terumo Kabushiki Kaisha Veículo sensível ao ph e método de preparação do mesmo, e droga sensível ao ph e composição medicamentosa sensível ao ph contendo o veículo, e método de cultura usando o mesmo
BR112016030341A8 (pt) * 2014-06-27 2021-07-20 Medytox Inc formulação para a remoção não cirúrgica de um depósito de gordura localizada em um indivíduo, método para a remoção não cirúrgica de depósitos de gordura localizada em um indivíduo que tem acúmulo de gordura localizada, e kit
US12616651B2 (en) 2014-11-21 2026-05-05 Lipodissolve Therapeutics Inc. Topical lipolysis composition and methods
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
WO2019150594A1 (ja) 2018-01-31 2019-08-08 株式会社ユニッシュ ホスファチジルコリン経皮吸収製剤
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
WO2019203543A1 (ko) * 2018-04-18 2019-10-24 (주)인벤티지랩 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법
KR102939043B1 (ko) 2020-06-01 2026-03-16 코스메드 파마소티컬 씨오 쩜 엘티디 미용용 마이크로니들 어레이
CN116889548B (zh) * 2022-03-31 2026-07-21 四川汇宇制药股份有限公司 一种脂质体递药系统及其制备方法和用途
KR20260079596A (ko) 2023-09-27 2026-06-02 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. 리포좀 약물 전달 시스템 및 이의 제조 방법, 리포좀 제제, 용도, 이를 포함한 체지방 감소 약물 또는 의료 미용 제품

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556592C2 (de) * 1975-12-16 1986-10-09 A. Nattermann & Cie GmbH, 5000 Köln Arzneimittelzubereitungen auf Basis öliger Lösungen von Phospholipiden
DE4122744C2 (de) * 1990-08-06 1994-02-03 Nattermann A & Cie Wäßriges Liposomensystem und Verfahren zu seiner Herstellung
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
DE4308121A1 (de) 1993-03-15 1994-09-22 Rhone Poulenc Rorer Gmbh Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems
ITMI20011182A1 (it) * 2001-06-05 2002-12-05 Indena Spa Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1684722A2 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699490A2 (de) * 2003-12-22 2006-09-13 Sanofi-Aventis Deutschland GmbH Medikament se lipolyse von fettansammlungen
RU2549966C2 (ru) * 2010-04-29 2015-05-10 Лихтблик Гмбх Применение фосфолипид-содержащей композиции для удаления подкожных скоплений жира посредством подкожного липолиза
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
US9844520B2 (en) 2015-02-27 2017-12-19 John Daniel Dobak, III Reduction of adipose tissue
US10485767B2 (en) 2015-02-27 2019-11-26 John Daniel Dobak, III Reduction of adipose tissue
US11065210B2 (en) 2015-02-27 2021-07-20 10Xbio, Llc Reduction of adipose tissue
US12133836B2 (en) 2015-02-27 2024-11-05 10Xbio, Llc Reduction of adipose tissue
US11298314B2 (en) 2017-04-21 2022-04-12 Ami Pharm Co., Ltd. Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same

Also Published As

Publication number Publication date
CN100482211C (zh) 2009-04-29
KR20060117914A (ko) 2006-11-17
HK1096857A1 (zh) 2007-06-15
CN1870977A (zh) 2006-11-29
ATE418965T1 (de) 2009-01-15
WO2005041919A3 (de) 2005-06-23
DE502004008793D1 (cg-RX-API-DMAC7.html) 2009-02-12
EP1684722B1 (de) 2008-12-31
JP2007509085A (ja) 2007-04-12
EP1684722A2 (de) 2006-08-02
DE10349979B4 (de) 2006-05-18
BRPI0415756A (pt) 2006-12-19
ES2319997T3 (es) 2009-05-18
CA2543187A1 (en) 2005-05-12
IL174525A0 (en) 2006-08-01
MXPA06004081A (es) 2006-06-27
DE10349979A1 (de) 2005-06-16
AU2004285264A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
EP1684722B1 (de) Medikamentöse gezielte lokale lipolyse
US20120329765A1 (en) Medicinal targeted local lipolysis
EP1699490A2 (de) Medikament se lipolyse von fettansammlungen
DE2907778C2 (cg-RX-API-DMAC7.html)
EP2563370B1 (de) Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse
US20100004216A1 (en) Medicinal lipolysis of accumulation of fat
DE1792410B2 (de) Arzneimittelzubereitung zur intravenösen Injektion
US9408857B2 (en) Medicinal cosmetic lipoatrophy
DE10221194B4 (de) Hyaluronidasehaltiges Hautpflegemittel
WO2008113421A1 (de) Neue pharmazeutische zusammensetzungen für die lipolyse und verfahren zu deren herstellung
DE2117762A1 (de) Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung
DE202007004776U1 (de) Neue pharmazeutische Zusammensetzungen für die Lipolyse
EP2244693A1 (de) Mittel zur intraartikulären injektion
WO1993013765A1 (fr) Solutions contenant des lecithines avec du levemopamil
HK1096857B (en) Medicamentously targeted local lipolysis
EP1747782A1 (en) Products for topical application comprising lysophospholipids and fatty acids
WO2004011004A1 (de) Liposomale formulierungen von phenylalanin-derivaten

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480031411.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 174525

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004765912

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004081

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2543187

Country of ref document: CA

Ref document number: 2006535989

Country of ref document: JP

Ref document number: 1020067007762

Country of ref document: KR

Ref document number: 2004285264

Country of ref document: AU

Ref document number: 1372/CHENP/2006

Country of ref document: IN

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2004285264

Country of ref document: AU

Date of ref document: 20041009

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004285264

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004765912

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067007762

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0415756

Country of ref document: BR